Abstract
Programming an anti-flu strategy: A new and potent neuraminidase inhibitor that maintains long-term systemic exposure of an antibody and the therapeutic activity of the neuraminadase inhibitor zanamivir has been created. This strategy could provide a promising new class of influenza A drugs for therapy and prophylaxis, and validates enzyme inhibitors as programming agents in synthetic immunology.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Antibodies, Monoclonal / chemistry*
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / pharmacology
-
Antiviral Agents / chemistry*
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / pharmacology
-
Click Chemistry
-
Fructose-Bisphosphate Aldolase / immunology
-
Humans
-
Immunoconjugates / chemistry*
-
Immunoconjugates / pharmacokinetics
-
Immunoconjugates / pharmacology
-
Influenza A virus / drug effects
-
Influenza A virus / enzymology*
-
Influenza, Human / drug therapy
-
Influenza, Human / virology
-
Mice
-
Models, Molecular
-
Neuraminidase / antagonists & inhibitors*
-
Neuraminidase / metabolism
-
Orthomyxoviridae Infections / drug therapy
-
Orthomyxoviridae Infections / virology
-
Zanamivir / chemistry*
-
Zanamivir / pharmacokinetics
-
Zanamivir / pharmacology
Substances
-
Antibodies, Monoclonal
-
Antiviral Agents
-
Immunoconjugates
-
Neuraminidase
-
Fructose-Bisphosphate Aldolase
-
Zanamivir